NCT07187570RecruitingPhase 3
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care
Source: ClinicalTrials.gov · Last updated 23 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation? Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation. Persons with atrial fibrillation who are planned for an electric cardioversion will: * Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1600 (estimated)
- First submitted
- 3 Jun 2025
- Start date
- 3 Jun 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- Region Stockholm
- Diseases
- Atrial fibrillation
- NCT number
- NCT07187570
- EU CT number
- 2024-513719-28-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 1600
- From 3 Jun 2025 to the primary completion date, Dec 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with an SGLT2 inhibitor.
- Prior/current diagnosis of heart failure.
- Contraindications to SGLT2 inhibitors.
Other illness
- Type 1 diabetes mellitus.
- Any condition or circumstance in which the patient should not participate in the study according to the study investigator.
Lab values
- Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2.
Other
- Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).
Who the study is looking for
- Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date.
- Age ≥ 55 years.
- Provided written informed consent.
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Danderyds Sjukhus AB Coordinator of this site? Confirm its status | Danderyd | Sweden | Recruiting |
| Karolinska University Hospital Coordinator of this site? Confirm its status | Huddinge | Sweden | Recruiting |
| Region Oestergoetland Coordinator of this site? Confirm its status | Linkoping | Sweden | Recruiting |
| Region Oerebro Laen Coordinator of this site? Confirm its status | Orebro | Sweden | Recruiting |
| Soedersjukhuset AB Coordinator of this site? Confirm its status | Stockholm | Sweden | Recruiting |
| Region Vaesterbotten Coordinator of this site? Confirm its status | Umea | Sweden | Recruiting |
| Uppsala University Hospital Coordinator of this site? Confirm its status | Uppsala | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.